Compare VRA & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | GNLX |
|---|---|---|
| Founded | 1982 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.2M | 133.0M |
| IPO Year | 2010 | 2022 |
| Metric | VRA | GNLX |
|---|---|---|
| Price | $3.77 | $2.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | ★ 227.6K | 199.2K |
| Earning Date | 06-10-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.47 | 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $416,097,000.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $2.29 |
| 52 Week High | $4.39 | $8.54 |
| Indicator | VRA | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 45.57 |
| Support Level | $3.02 | $2.73 |
| Resistance Level | $3.80 | $3.00 |
| Average True Range (ATR) | 0.19 | 0.15 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 4.78 | 15.79 |
Vera Bradley Inc designs women's handbags, luggage, and travel items, fashion and home accessories, and gifts. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct and Vera Bradley Indirect.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.